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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is a growing concern in meeting global targets for TB
control. In high-income low-TB-incidence countries, a disproportionate number of MDR-TB cases occur in migrant
(foreign-born) populations, with concerns about low adherence rates in these patients compared to the host non-
migrant population. Tackling MDR-TB in this context may, therefore, require unique approaches. We conducted a
systematic review and meta-analysis to identify and synthesise data on MDR-TB treatment adherence in migrant
patients to inform evidence-based strategies to improve care pathways and health outcomes in this group.
Methods: This systematic review and meta-analysis was conducted in line with PRISMA guidelines (PROSPERO
42017070756). The databases Embase, MEDLINE, Global Health and PubMed were searched to 24 May 2017 for
primary research reporting MDR-TB treatment adherence and outcomes in migrant populations, with no restrictions
on dates or language. A meta-analysis was conducted using random-effects models.
Results: From 413 papers identified in the database search, 15 studies reporting on MDR-TB treatment outcomes
for 258 migrants and 174 non-migrants were included in the systematic review and meta-analysis. The estimated
rate of adherence to MDR-TB treatment across migrant patients was 71% [95% confidence interval (CI) = 58–84%],
with non-adherence reported among 20% (95% CI = 4–37%) of migrant patients. A key finding was that there were
no differences in estimated rates of adherence [risk ratio (RR) = 1.05; 95% CI = 0.82–1.34] or non-adherence (RR = 0.
97; 95% CI = 0.79–1.36) between migrants and non-migrants.
Conclusions: MDR-TB treatment adherence rates among migrants in high-income low-TB-incidence countries are
approaching global targets for treatment success (75%), and are comparable to rates in non-migrants. The findings
highlight that only just over 70% of migrant and non-migrant patients adhere to MDR-TB treatment. The results
point to the importance of increasing adherence in all patient groups, including migrants, with an emphasis on
tailoring care based on social risk factors for poor adherence. We believe that MDR-TB treatment targets are not
ambitious enough.
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Background
Multidrug-resistant tuberculosis (MDR-TB), defined by
resistance to isoniazid and rifampicin, the two front-line
antimicrobial drugs used to treat TB, presents substan-
tial barriers to the eradication of global TB due to chal-
lenges around diagnosis and successful treatment [1–4].
As a result, MDR-TB has become a major focus for TB
research in recent years [1, 2], with 480,000 new MDR-
TB cases recorded in 2015 [1], comprising 5% of the
total global TB burden [5]. Current evidence suggests
that MDR-TB will increase globally as a proportion of
total TB cases, not only due to transmission of MDR-TB
[6, 7], but also poor adherence to TB treatment leading
to the emergence of MDR-TB [1, 8–11]. World Health
Organization (WHO) global targets for MDR-TB treat-
ment success and adherence are currently 75%, which is
lower than the 85% target for drug-sensitive TB [1, 12],
reflecting both the higher rates of mortality and barriers
to treatment adherence.
It is estimated that there are over 244 million inter-
national migrants worldwide [13], with rates of migration
increasing, which has significant implications for global
health and health systems internationally [14, 15]. In many
high-income low-TB-incidence countries, migrant (for-
eign-born) populations experience a disproportionate bur-
den of TB and MDR-TB [16–18]. Furthermore, they are
suggested to have poorer treatment outcomes, with 5.2%
of non-UK-born TB cases notified as being lost to follow-
up, compared to only 1.5% among UK-born TB cases [19].
As a result, they have received particularly close attention
in targeted TB initiatives [20, 21], with specific frame-
works now being drawn up globally to tackle TB and
MDR-TB within these communities [22].
MDR-TB treatment regimens may be of long duration.
Whilst a shorter 9-month Bangladesh treatment regimen
is available for some patients, in many cases MDR-TB
treatment requires an intensive treatment phase up to
8 months in duration, with a further 12-month mini-
mum continuation phase [23]. Treatment for MDR-TB
typically utilises at least five active drugs depending on
the specific resistance profile of the infection and in-
cludes second-line drugs, which have increased toxicity,
worse side effects, greater treatment burden (e.g. num-
ber of pills) and reduced individual efficacy [1, 21, 23–
27]. As a result of these factors, adherence rates are typ-
ically lower than for drug-sensitive TB, though the con-
sequences of non-adherence are more severe. There are
currently limited data on MDR-TB treatment adherence
in migrant patients, and a lack of clarity in health initia-
tives globally as to the priorities for improving care –
and ultimately treatment outcomes – in these popula-
tions [1, 28]. Though there is an insufficient evidence
base regarding treatment outcomes for MDR-TB in mi-
grant populations and factors impacting on adherence,
TB control strategies are increasingly targeting migrant
groups and there is an emphasis on improving the detec-
tion and treatment of TB and MDR-TB in migrants. A
robust assessment of adherence to MDR-TB treatment
regimens is, therefore, necessary to assess progress
against treatment goals and to inform policy and
practice.
Methods
The aim of this systematic review and meta-analysis is,
therefore, to identify and synthesise data on MDR-TB
treatment adherence in migrant populations.
Protocol and registration
This research was carried out in line with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [29], and registered with PROS-
PERO (42017070756).
Search strategy and inclusion and exclusion criteria
We included peer-reviewed papers reporting primary data
on MDR-TB treatment adherence in migrants (foreign-
born and receiving treatment outside their country of
birth). Those studies reporting stipulated WHO outcomes
for individuals receiving MDR-TB treatment that could be
used as proxies for treatment adherence (cured, treatment
completed, treatment failure, lost to follow-up or not eval-
uated) were included [30, 31], as well as studies reporting
other outcomes in line with the WHO outcome measures
(still on treatment, unsuccessful outcome or successful
outcome) [32]. These treatment outcomes were included
to comprehensively identify and examine available data on
treatment adherence in migrants. The use of treatment
outcomes as a proxy for treatment adherence enabled the
most comprehensive examination of available data on
treatment adherence among migrants, and is often used in
population-based assessments. However, sensitivity ana-
lyses were also conducted to explore further treatment ad-
herence specifically.
Studies were not excluded based on publication date
or language, and non-English papers were translated
prior to full-text screening. There were also no restric-
tions on whether studies considered paediatric or adult
populations, or the type of study design. Studies defining
migrant status according to ethnic or ancestral back-
ground but not country of birth were excluded, as were
papers where primary data were not reported (e.g. com-
ments, editorials, letters and reviews).
We searched the databases Embase (1947 to 22 May
2017), Global Health (1973 to 24 May 2017), MEDLINE
(1946 to 22 May 2017) and PubMed (1993 to 22 May
2017) using a Boolean search strategy with keywords
and relevant medical subheadings (MeSH) pertaining to
four main themes: migrants, adherence, tuberculosis
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and drug resistance (including MDR-TB). The terms
used were identified by consulting the literature, previ-
ous systematic reviews [20, 33] and experts in these
areas. The search strategy is available in the Appendix.
Additional relevant papers were also identified through
hand searching the bibliographies of publications in-
cluded after full-text screening, as well as related infor-
mation sources, including: the Global Fund, Public
Health England, WHO and the International Union
Against Tuberculosis and Lung Disease. Experts in the
field were also consulted to identify additional relevant
papers.
Screening and data management
Two reviewers duplicated the title and abstract screen-
ing and full-text screening (LBN and KR), which was
carried out using the web-based application Rayyan [34].
Data extraction and quality assessment for all papers
included were also conducted by two reviewers (LBN
and KR). Using a piloted data extraction form, summary
data were extracted on study design, dates, location, pa-
tient characteristics, type of treatment, and migrant and
non-migrant treatment outcomes in line with WHO
outcome measures. Quality assessment was carried out
using established appraisal tools. All case series were
assessed using the Case Series Critical Appraisal Tool of
the Joanna Briggs Institute [35]. Case–control studies
were assessed using the Critical Appraisal Skills Program
(CASP) appraisal tool [36]. Cohort studies were assessed
using the CASP cohort checklist [37]. Using these tools,
papers were given a quality score. For case-series and
cohort tools, scores were calculated as a total out of the
maximum number of applicable questions.
Data analysis
Statistical analysis was carried out using Stata 13 [38].
The commands metaprop and metan were used to cal-
culate pooled prevalence and pooled risk ratios (RRs),
respectively, with corresponding 95% confidence inter-
vals (CIs) [39, 40]. Heterogeneity between studies was
examined using the I2 statistic. Due to the heterogeneity
of the included studies, analyses utilised random-effects
models [40].
We estimated the pooled proportion of migrants who
were adherent and not adherent to treatment. We carried
out analyses for both of these categories, as neither cap-
ture individuals who have died. We defined adherent indi-
viduals as those reported as cured, having completed
treatment or with a successful outcome, utilising these
treatment outcomes as indicators of treatment adherence
to examine all available evidence comprehensively. Indi-
viduals considered adherent have, therefore, had confirm-
ation of MDR-TB cure or have satisfactorily completed a
full course of treatment. Successful outcomes cover both
of these categories. Those still on treatment were excluded
from the adherent variable as data were not available on
treatment outcome. However, sensitivity analyses were
conducted to examine the effect of these patients on
pooled adherence rates across the studies if they were ad-
herent or non-adherent.
We defined non-adherent individuals as those re-
ported in the literature within categories: lost to follow-
up, treatment default (discontinuation of treatment),
treatment failure (which can often be attributed to issues
in adherence) and unsuccessful outcome. Patients who
transferred out of treatment were excluded from the
non-adherent group as data on outcome were not
known. A sensitivity analysis was conducted excluding
treatment failure, as this outcome may be due to factors
other than non-adherence.
We also carried out meta-analyses comparing rates of
adherence and non-adherence between migrants and
non-migrants across the included studies. These meta-
analyses excluded studies in which no events occurred
in either the migrant or non-migrant arms (both-armed
zero-event studies [41, 42]), although these data are cap-
tured in the pooled proportions enabling comparison be-
tween migrants and non-migrants.
Results
Screening results
Database searches yielded 413 publications, with 234
publications carried forward for title and abstract
screening after the removal of duplicates. Of those, 129
citations were excluded. The full texts of 105 publica-
tions were screened, including one citation identified
through bibliography screening, hand searching of rele-
vant sites, and recommendations from experts. Ninety
one records were excluded during full-text screening,
and the reasons for their exclusion recorded (Fig. 1).
Altogether, 15 publications met the inclusion criteria
and were included in the review and meta-analysis
(Fig. 1).
Study characteristics
The publications included in the analyses comprised
seven cohort studies, six case series and two case–con-
trol studies, containing data from 1986 to 2014. All stud-
ies labelled as case series were described as such in the
relevant papers, and are inclusive of all cases during the
relevant study period for each data set. Studies were
conducted in 11 countries: Canada (2) [43, 44], Australia
(2) [32, 45], Czech Republic (1) [46], Finland (1) [47],
France (1) [48], Germany (1) [49], Iran (1) [50], Italy (3)
[51–53], New Zealand (1) [54], Switzerland (1) [55] and
USA (1) [56] (Table 1). A number of studies indicated
that treatment was provided at specialist TB centres or
centres that otherwise specialised in infectious and
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Fig. 1 PRISMA flow diagram of study selection process [29]. It includes reasons for exclusion at the full-text screening stage. DS-TB drug-sensitive
tuberculosis, MDR-TB multidrug-resistant tuberculosis
Table 1 Characteristics of studies included
Citation Study type Location Years with data Migrant (N) Non-migrant (N) Study quality
Avendano, 2000 [43] Cohort Canada 1986–1999 38 2 9/9
Bartu et al., 2010 [46] Case–control Czech Republic 2001–2009 17 33 7/9
Blaas et al., 2008 [49] Case series Germany 1997–2006 4 nr 9/9
Cameron & Harrison, 1997 [54] Case series New Zealand 1988–1995 7 1 7/9
Donnan et al., 2017 [32] Case series Australia 2005–2014 14 nr 9/10
Ferrara et al., 2005 [51] Cohort Italy 1995–1999 39 88 9/9
Ferrer et al., 2010 [56] Cohort USA 1994–2007 48 nr 9/9
Flament-Saillour et al., 1999 [48] Case–control France 1994–1996 32 19 8/9
Judge et al., 2016 [45] Case series Australia 2004–2013 6 nr 7/9
Kherad et al., 2009 [55] Cohort Switzerland 1999–2003 5 nr 11/11
Manfredi et al., 2009 [52] Cohort Italy 2006–2008 2 nr 7/9
Masjedi et al., 2008 [50] Cohort Iran 2002–2006 28 23 9/9
Mignone et al., 2014 [53] Case series Italy 2006–2010 1 1 8/9
Minion et al., 2013 [44] Case series Canada 1997–2008 3 2 10/10
Vasankari et al., 2012 [47] Cohort Finland 1994–2005 14 5 9/9
nr not reported
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pulmonary diseases [43, 46, 50, 52, 55], whilst the
remaining studies either did not indicate the institutions
providing treatment or were based on national-level
data. Data were not consistently reported on migrant
characteristics, including the reason for migration, time
since migration or country of origin. Of the included stud-
ies reporting migrant status, it was typically stated only
whether a patient was foreign-born, whilst two studies
have a clearly identifiable population of cross-border and
binational individuals who are largely migrating for treat-
ment as opposed to permanent settlement [32, 56].
A total of 258 migrants with MDR-TB were included in
the studies. For nine studies, we were able to disaggregate
data for 174 non-migrants with MDR-TB or extensively
drug-resistant tuberculosis [43, 44, 46–48, 50, 51, 53, 54].
The quality of the included studies was high, with the
number of criteria met ranging from 7/9 to 11/11 for co-
hort studies, 7/9 to 10/10 for case series, and 7/9 [46]
and 8/9 [48] for the two case–control studies included.
Studies were not excluded based on study quality.
Quality scores for each study are reported in Table 1.
Comparable rates of MDR-TB treatment adherence among
migrants and non-migrants
MDR-TB treatment adherence among the 248 migrants
across the included studies was 71% (95% CI = 58–84%;
I2 = 82%) after excluding individuals still on treatment
(n = 10) (Fig. 2). Among those who were considered ad-
herent, 76 were reported as cured, 36 as having com-
pleted treatment, with a further 47 reported as having
successful outcomes. Sensitivity analyses in which mi-
grants still on treatment were reintroduced gave a rate
ranging from 66% to 72%, depending on whether the in-
dividuals were assumed to be non-adherent or adherent.
A meta-analysis was conducted utilising the nine stud-
ies for which the outcomes of 179 migrants and 171
non-migrants were disaggregated, enabling a comparison
of MDR-TB treatment adherence in these two groups
(Fig. 3). Migrant adherence to MDR-TB treatment was
found to be comparable to non-migrant adherence (RR
= 1.05, 95% CI = 0.82–1.34; I2 = 32.5%).
Rates of non-adherence to MDR-TB treatment similar in
migrants compared to non-migrants
Complementary analyses examining rates of non-
adherence in migrants were also conducted, as patients
who have died are not captured by either measure. Among
the 248 migrants with reported MDR-TB treatment ad-
herence outcomes, 61 were considered non-adherent
while 17 individuals transferred out of treatment and were
excluded. The estimated rate of non-adherence to MDR-
TB treatment in migrants was 20% (95% CI = 4–37%; I2 =
67.32%) (Fig. 4). This rate included 17 individuals lost to
follow-up, 23 who discontinued treatment and 21
Fig. 2 Pooled proportion of migrants adherent to MDR-TB treatment regimens. Treatment completion and cure are considered adherent. Individuals
on treatment are excluded. CI confidence interval, MDR-TB multidrug-resistant tuberculosis
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Fig. 3 Meta-analysis of adherence in migrant vs. non-migrant populations. Treatment completion and cure are considered adherent. CI confidence interval
Fig. 4 Pooled proportion of migrants not adherent to MDR-TB treatment. Treatment failure, discontinuation of treatment, loss to follow-up and
unsuccessful outcomes are considered non-adherent. CI confidence interval, MDR-TB multidrug-resistant tuberculosis
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individuals with reported treatment failure. However, when
treatment failure was excluded, as this may be due to other
factors besides non-adherence (and risks stigmatising pa-
tients through the attribution of treatment failure to poor
adherence), the rate of non-adherence decreased to 11%
(95% CI = 4–19%; I2 = 92.64%). In non-migrants, the rate of
non-adherence when excluding treatment failure was 3%
(95% CI = 0–8%; I2 = 9.92%).
Rates of non-adherence to MDR-TB treatment were
compared between migrants and non-migrants in six
studies for which data were available (Fig. 5), and were
found to be comparable in migrant and non-migrant
populations (RR = 0.97, 95% CI = 0.70–1.36; I2 = 0%).
Discussion
Adherence rates among migrants on treatment for
MDR-TB were estimated to be 71% (95% CI = 58–84%),
approaching global treatment adherence targets [12],
and exceeding previous reports estimating adherence
rates in the general population as 49–63.5% [57, 58].
This raises questions about whether more ambitious tar-
gets should be set for MDR-TB treatment adherence
globally, and suggests that adherence may be dependent
on social risk factors and treatment context, not only
migrant status.
Rates of MDR-TB treatment adherence and non-
adherence were also found to be comparable between
migrants and non-migrants (RR = 1.05, 95% CI = 0.82–
1.34 and RR = 0.97, 95% CI = 0.70–1.36, respectively).
These findings challenge previous assumptions that ad-
herence to MDR-TB treatment is likely to be worse in
migrants [1, 21, 59, 60].
Social risk factors, for example social deprivation, vul-
nerable housing, mental health concerns or other co-
morbidities, have been shown to present barriers to care
in migrant populations, and may contribute to poorer
treatment adherence [61–64]. Being a highly mobile
population with poor access or entitlement to high-
quality health care may also present significant barriers
to adhering to treatment, as might language or health lit-
eracy barriers. The legal complexities of a migrant’s sta-
tus can also lead to non-adherence, although at times it
is involuntary. For example, the right to stay within a
country whilst receiving treatment is a facilitator of
greater adherence [62]. In some contexts, it may be that
migrants may perceive that their adherence to treatment
(and cure) may impact on their status (e.g. leave to re-
main) in host countries. However, there is also evidence
to suggest that insecure migrant status is associated with
non-completion of treatment, with migrants potentially
hiding or absconding from treatment centres for fear of
deportation [26, 62, 65]. There are even cases of illegal
and undocumented migrants with TB being deported,
interrupting treatment and likely facilitating the spread
of resistance [66]. Practices such as the current sharing
of patient data with the Home Office for immigration
enforcement purposes in the UK may contribute to non-
adherence, as patients are concerned that contact with
health services may result in their deportation [67].
The health service context within which MDR-TB is
diagnosed and treated may also be a significant deter-
minant of adherence, and may mediate the effects that
social and cultural barriers may have (particularly in the
context of more intensive treatment programmes or
hospitalisation) [24, 61, 68]. The findings may also be
Fig. 5 Meta-analysis of non-adherence to MDR-TB treatment regimens in migrant vs. non-migrant populations. Treatment failure, discontinuation of
treatment, loss to follow-up and unsuccessful outcomes are considered non-adherent. CI confidence interval, MDR-TB multidrug-resistant tuberculosis
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driven by an emphasis on individualised treatment regi-
mens [57], with evidence that adherence was improved
among patients in specialist institutions (e.g. centres spe-
cialising in TB or pulmonary diseases), which may be
better equipped to support treatment adherence [27, 46,
48], though it was not feasible given the available data to
conduct a meta-analysis on this. The overrepresentation
of high-income low-TB-incidence countries across the
studies, which may have health infrastructures that are
better equipped to support treatment adherence in
MDR-TB patients and may also have targeted care or
support for migrant service users, may also have con-
tributed to the treatment adherence rates seen [69].
Across the included studies, it was also suggested that
adherence rates have increased in recent years, which is
likely to reflect an improvement in the provision of MDR-
TB treatment and increased availability of specialist TB
services [70, 71]. Whilst other factors such as increasing
TB programme visibility, provision of information,
patient-centred interactions with health-care providers
and approaches to minimising or managing treatment side
effects are also likely to impact on treatment outcomes
[72], data were not available to allow a comprehensive
examination of these factors.
The comparable rates of adherence (and non-
adherence) between migrants and non-migrants are in
contrast with assumptions that adherence to TB treat-
ment is likely to be worse in migrants [1, 21, 59, 60],
and highlight the importance of ensuring that MDR-TB
treatment pathways have the capacity to support patients
experiencing risk factors for poor adherence, regardless
of their migrant status. Furthermore, it is essential that
patient groups are not marginalised or scapegoated be-
cause of their migrant status, but rather the focus of
adherence-improvement strategies should remain on ad-
dressing key barriers to adherence.
This research represents the first systematic and com-
prehensive examination of adherence to MDR-TB treat-
ment in migrant populations, to our knowledge. It
identifies the need for a stronger evidence base in light
of the lack of data collected on migrant status in TB and
MDR-TB patients, though this group is a key focus of
TB strategies in high-income low-TB-incidence coun-
tries given the increased burden of TB and MDR-TB in
migrant populations in low-incidence countries [1, 2,
12], for example the Collaborative TB Strategy for Eng-
land [73]. This should include a comprehensive examin-
ation of available evidence on adherence to drug-
sensitive TB to complement this synthesis of data on
MDR-TB, a key area for further investigation given the
limited reporting of treatment completion by migrant
status and the impact that poor adherence in treatment
for drug-sensitive TB may have on the emergence of
MDR-TB. Whilst the review illuminated some factors
that may contribute to MDR-TB treatment adherence
(or non-adherence), there remains a need for further re-
search to improve understandings of drivers of MDR-TB
treatment adherence and non-adherence within migrant
populations, and to delineate where these mechanisms
differ from non-migrant populations. Such research, in-
cluding both quantitative and qualitative research, is
needed to tailor interventions better to support treat-
ment adherence in underserved groups and will require
robust and consistent data collection around social risk
factors and migrant status in MDR-TB patients.
Though this review addresses a significant gap in know-
ledge on MDR-TB treatment adherence in migrants, the
research highlights a number of important limitations in
the evidence base that should be taken into account when
considering the results. First, the findings should be
considered in the context of the use of treatment out-
comes as a proxy for adherence, which enabled us to
examine the available data comprehensively and highlights
the key implications for clinical pathways.
The review highlighted the significant lack of research
in which data are disaggregated in such a way that makes
specific research into treatment adherence in MDR-TB
and different risk groups feasible. This significantly limited
the number of papers included in the review, with the ma-
jority of exclusions at full-text screening being attributed
to an inability to disaggregate migrant status or drug
susceptibility status in relation to treatment adherence.
An additional factor limiting the inclusion of papers in
this review is the inconsistent reporting of migrant status
in the evidence base or frequent use of ethnicity as a proxy
for migration. Whilst the review sought to identify peer-
reviewed primary research reporting data on migrant
groups comprehensively, papers that have not included
routinely utilised migrant terms (see the Appendix) may
not, thus, be identified in migrant health searches, such as
that conducted here.
The total number of studies included in the analysis
highlights the insufficient research on the relationship
between migration and treatment adherence in MDR-
TB. The lack of evidence in this area is concerning in
light of the growing emphasis in both policy and practice
in high-income countries on targeting migrants in the
detection and treatment of MDR-TB [73–75].
Data across the included studies were also heteroge-
neous, reflecting the diverse migrant populations and set-
tings represented. Whilst the analyses utilised random-
effects models, it is also useful to interpret the findings in
light of the differences across studies. A further limitation
of the available data is the small sample sizes across stud-
ies, which are partly attributed to the low incidence of
MDR-TB, high rates of loss to follow-up during the
lengthy MDR-TB treatment pathway (and, thus, the small
numbers of patients for whom treatment completion data
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are available), and our particular interest in migrants as a
patient population. This only further highlights the need
to strengthen the available evidence base in this area.
There is also a risk of publication bias, as clinical data on
MDR-TB treatment are not systematically analysed or
published. Furthermore, the available data may reflect set-
tings in which migrants are a specific interest group (e.g.
due to being overrepresented), leading to decisions to rec-
ord or stratify data based on migrant status, which was an
inclusion criterion for this review.
Conclusions
Adherence to MDR-TB treatment is critical both in redu-
cing poorer and costlier individual health outcomes and in
preventing the transmission of MDR-TB. Despite the
comparable rates of adherence in migrants and non-
migrants, there are still a concerning number of individ-
uals failing to complete MDR-TB treatment, enabling the
spread of MDR-TB. This, therefore, calls into question
whether MDR-TB treatment targets are ambitious enough
and highlights the paramount importance of increasing
adherence in all patient groups, including migrants, with
an emphasis on tailoring care based on social risk factors
for poor adherence in addition to migrant status.
Appendix
Listed are representative search terms used in database
searches (Embase).
Brackets () denote MeSH terms highlighted by the
database.
1. Migrant* OR (migrant) OR (migrant worker) OR
migrat* OR (migration) OR refugee* OR (refugee)
OR asylum seeker* OR (asylum seeker) OR
foreigner* OR (foreign worker) OR foreign born OR
non-native* OR Immigra* OR (immigration) OR
(immigrant) OR emigra* OR (emigrant) OR
(Emigrants) OR (emigration) OR oversea* OR foreign
student* OR (foreign student) OR International
student* OR traffick*
2. Adher* OR complian* OR default OR concordan* or
treatment outcome* OR (treatment outcome) OR non
adher* OR (patient compliance) OR non-complian*
3. tuberculosis OR (TB) OR (drug resistant tuberculosis)
OR (Tuberculosis) OR (Mycobacterium tuberculosis)
OR (extensively drug resistant tuberculosis) OR
(multidrug resistant tuberculosis)
4. MDR* OR (drug resistance) OR (multidrug resistant
tuberculosis) OR (multidrug resistance) OR
multidrug resist* OR multi-drug resist* OR
multidrug-resist* OR XDR* OR (extensively drug
resistant tuberculosis) OR extensively drug resistant)
OR TDR* OR (Totally drug resistant)
5. 1 AND 2 AND 3 AND 4
Abbreviations
CASP: Critical Appraisal Skills Program; CI: Confidence interval; DS-TB: Drug-
sensitive tuberculosis; MDR-TB: Multidrug-resistant tuberculosis;
MeSH: Medical subheadings; PRISMA: Preferred Reporting Items for
Systematic Reviews and Meta-Analyses; RR: Risk ratio; TB: Tuberculosis;
WHO: World Health Organization
Acknowledgments
Not applicable.
Funding
The authors receive funding from the UK National Institute for Health
Research Imperial Biomedical Research Centre, the Imperial College
Healthcare Charity, the Wellcome Trust (Grant number 209993/Z/17/Z) and
the European Society for Clinical Microbiology and Infectious Diseases
(ESCMID) through the ESCMID Study Group for Infections in Travellers and
Migrants (ESGITM) Research Funding.
Availability of data and materials
The study protocol can be accessed on PROSPERO (42017070756). Additional
data not presented in the manuscript can be obtained by contacting the
authors.
Authors’ contributions
All authors contributed to the conceptualisation and design of the research.
LBN and KR carried out the database search, screening, quality assessment,
data extraction and analysis, and contributed to the writing of the
manuscript in collaboration with SH and JSF. All authors read and approved
the final manuscript.
Authors’ information
All authors have extensive experience in research on infectious diseases in
migrant populations, with a focus on TB and MDR-TB in these communities.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 31 August 2017 Accepted: 21 December 2017
References
1. World Health Organization. Global Tuberculosis Report. 2016. http://apps.
who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.
2. World Health Organization. The end TB strategy. 2015. http://www.who.int/
tb/End_TB_brochure.pdf?ua=1.
3. Malin AS, McAdam KP. Escalating threat from tuberculosis: the third
epidemic. Thorax England. 1995;50 Suppl 1:S37–42.
4. Frieden TR, Fujiwara PI, Washko RM. Tuberculosis in New York City – turning
the tide. N Engl J Med. 1995:229–33. http://ovidsp.ovid.com/ovidweb.cgi?T=
JS&PAGE=reference&D=emed6&NEWS=N&AN=25221660.
5. World Health Organization. Drug-resistant TB: surveillance and response.
2014. http://www.who.int/tb/publications/global_report/gtbr14_
supplement_web_v3.pdf.
6. Nsofor CA, Jiang Q, Wu J, Gan M, Liu Q, Zuo T, et al. Transmission is a
noticeable cause of resistance among treated tuberculosis patients in
Shanghai. China Sci Rep. 2017;7:7691.
7. Dobler CC, Korver S, Batbayar O, Nyamdulam B, Oyuntsetseg S, Tsolmon B,
et al. Multidrug-resistant tuberculosis in patients for whom first-line
treatment failed, Mongolia, 2010–2011. Emerg Infect Dis. 2015;21:1451–4.
Nellums et al. BMC Medicine  (2018) 16:27 Page 9 of 11
8. GBC Health. Drug-resistant TB: why it matters. 2011. http://www.gbchealth.
org/system/documents/category_1/7/GBCHealth Issue Brief_Drug-Resistant
TB.pdf. Accessed 10 July 2017.
9. Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg
HM. Acquired drug resistance in Mycobacterium tuberculosis and poor
outcomes among patients with multidrug-resistant tuberculosis. Emerg
Infect Dis. 2015;21:992–1001. http://www.ncbi.nlm.nih.gov/pubmed/
25993036, Accessed 23 July 2017.
10. Gao J, Ma Y, Du J, Zhu G, Tan S, Fu Y, et al. Later emergence of acquired drug
resistance and its effect on treatment outcome in patients treated with
standard short-course chemotherapy for tuberculosis. BMC Pulm Med. 2016;16:
26. http://www.biomedcentral.com/1471-2466/16/26, Accessed 23 July 2017.
11. Sharma A, Hill A, Kurbatova E, van der Walt M, Kvasnovsky C, Tupasi TE, et
al. Estimating the future burden of multidrug-resistant and extensively drug-
resistant tuberculosis in India, the Philippines, Russia, and South Africa: a
mathematical modelling study. Lancet Infect Dis. 2017;17:707–15. http://
www.ncbi.nlm.nih.gov/pubmed/28499828, Accessed 22 July 2017.
12. World Health Organization. The global plan to stop TB 2011–2015. 2011.
http://apps.who.int/iris/bitstream/10665/44437/1/9789241500340_eng.pdf.
13. International Organisation for Migration. Global Migration. Data Briefing. 2014;45.
14. Zimmerman C, Kiss L, Hossain M, Busse R, Palm W. Migration and health: a
framework for 21st century policy-making. PLoS Med. 2011;8:e1001034.
http://dx.plos.org/10.1371/journal.pmed.1001034, Accessed 21 July 2017.
15. International Organisation for Migration. Migration flows – Europe. http://
migration.iom.int/europe/. Accessed 31 July 2017.
16. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, et al.
Towards tuberculosis elimination: an action framework for low-incidence
countries. Eur Respir J. 2015;45:928–52. http://www.ncbi.nlm.nih.gov/
pubmed/25792630, Accessed 25 Sept 2017.
17. Centers for Disease Control and Prevention. International Organisation for
MigrationTrends in Tuberculosis – United States. 2016. https://www.cdc.gov/
tb/publications/factsheets/statistics/tbtrends.htm. Accessed 15 July 2017.
18. Public Health England. Tuberculosis in England. 2016. www.gov.uk/phe.
19. Public Health England. TB Annual Report. 2017.
20. Faustini A, Hall AJ. Risk factors for multidrug resistant tuberculosis in Europe: a
systematic review. Univers J Public Heal. 2012;3:65–70. http://ovidsp.ovid.com/
ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=2006080569.
21. International Organization for Migration. Migration & tuberculosis: a pressing
issue. 2012;1–4.
22. World Health Organization Regional Office for the Western Pacific.
Tuberculosis control in migrant populations: guiding principles and
proposed actions. 2016. p. 24.
23. World Health Organization. The shorter MDR-TB regimen. 2016. http://www.
who.int/tb/Short_MDR_regimen_factsheet.pdf. Accessed 11 Aug 2017.
24. World Health Organization. WHO treatment guidelines for drug- resistant
tuberculosis. 2016. http://apps.who.int/iris/bitstream/10665/250125/1/
9789241549639-eng.pdf?ua=1.
25. Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse events
associated with the treatment of multidrug-resistant tuberculosis. Am J Ther.
2016;23:e521–30. http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:
landingpage&an=00045391-201603000-00024, Accessed 5 June 2017.
26. Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK, Das M. When treatment is
more challenging than the disease: a qualitative study of MDR-TB patient
retention. PLoS One..2016. http://www.plosone.org/article/fetchObject.
action?uri=info:doi/.10.1371/journal.pone.0150849&representation=PDF
27. Lönnroth K, Mor Z, Erkens C, Bruchfeld J, Nathavitharana RR, van der Werf MJ,
et al. Tuberculosis in migrants in low-incidence countries: epidemiology and
intervention entry points. Int Tuberc Lung Dis. 2017;21:624–36. http://www.
ingentaconnect.com/content/10.5588/ijtld.16.0845, Accessed 25 Sept 2017.
28. Devillé W, Greacen T, Bogic M, Dauvrin M, Dias S, Gaddini A, et al. Health
care for immigrants in Europe: is there still consensus among country
experts about principles of good practice? A Delphi study. BMC Public
Health. 2011;11:699. http://bmcpublichealth.biomedcentral.com/articles/10.
1186/1471-2458-11-699, Accessed 21 July 2017.
29. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS Med. 2009;6:e1000097. http://www.ncbi.nlm.nih.gov/
pubmed/19621072. Accessed 11 July 2017.
30. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al.
Speaking the same language: treatment outcome definitions for multidrug-
resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.
31. World Health Organization. Definitions and reporting framework for
tuberculosis. 2013. http://apps.who.int/iris/handle/10665/79199.
32. Donnan EJ, Coulter C, Simpson G, Clark J, Nourse C. Paediatric tuberculosis
in Queensland, Australia: overrepresentation of cross-border and indigenous
children. Int J Tuberc Lung Dis. 2017;21:263–9. http://ovidsp.ovid.com/
ovidweb.cgi?T=JS&PAGE=reference&D=prem&NEWS=N&AN=28225336.
33. Aldridge RW, Yates TA, Zenner D, White PJ, Abubakar I, Hayward AC. Pre-
entry screening programmes for tuberculosis in migrants to low-incidence
countries: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:
1240–9. http://www.sciencedirect.com/science/article/pii/
S1473309914709661, Accessed 22 May 2017.
34. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyann – a web
and mobile app for systematic reviews. Syst Rev. 2016;5:210. http://
systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-
0384-4, Accessed 11 July 2017.
35. Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal tools for
use in JBI systematic reviews – checklist for case series. 2016. http://
joannabriggs.org/research/critical-‐appraisal-‐tools.html. Accessed 8 Aug 2017.
36. Critical Appraisal Skills Programme. 11 questions to help you make sense of
case control study. 2017. http://docs.wixstatic.com/ugd/dded87_
afbfc99848f64537a53826e1f5b30b5c.pdf. Accessed 8 Aug 2017.
37. Critical Appraisal Skills Programme. 12 questions to help you make sense of
cohort study. http://docs.wixstatic.com/ugd/dded87_
5ad0ece77a3f4fc9bcd3665a7d1fa91f.pdf.
38. StataCorp. Stata statistical software: release 13. College Station, TX: StataCorp LP.
39. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-
analysis of binomial data. Arch Public Heal. 2014;72:39. http://
archpublichealth.biomedcentral.com/articles/10.1186/2049-3258-72-39,
Accessed 14 Aug 2017.
40. Sterne JA, Bradburn MJ, Egger M. Meta-analysis in StataTM. systematic
reviews in health care: meta-analysis in context. 2nd ed. 2008.
41. Cheng J, Pullenayegum E, Marshall JK, Iorio A, Thabane L. Impact of including or
excluding both-armed zero-event studies on using standard meta-analysis
methods for rare event outcome: a simulation study. BMJ Open. 2016;6:e010983.
http://www.ncbi.nlm.nih.gov/pubmed/27531725, Accessed 14 Aug 2017.
42. Cai T, Parast L, Ryan L. Meta-analysis for rare events. 2010. http://psych.
colorado.edu/~willcutt/pdfs/Cai_2010.pdf, Accessed 14 Aug 2017.
43. Avendano M. Multidrug-resistant tuberculosis: long term follow-up of 40
non-HIV-infected patients. Can Respir J. 2000;383–9. http://ovidsp.ovid.com/
ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=30952782.
44. Minion J, Gallant V, Wolfe J, Jamieson F, Long R, J. M, et al. Multidrug and
extensively drug-resistant tuberculosis in Canada 1997–2008: demographic
and disease characteristics. PLoS One. 2013;8. http://www.plosone.org/
article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.
pone.0053466&representation=PDF.
45. Judge D, Krause V. Multidrug-resistant tuberculosis in the Northern Territory:
a 10-year retrospective case series. Commun Dis Intell Q Rep Australia. 2016;
40:E334–9. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=
emex&NEWS=N&AN=614955365.
46. Bartu V, Kopecka E, Havelkova M. Factors associated with multidrug-resistant
tuberculosis: comparison of patients born inside and outside of the Czech
Republic. J Int Med Res. 2010;38:1156–63. http://ovidsp.ovid.com/ovidweb.
cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed12&AN=359212997.
47. Vasankari T, Soini H, Liippo K. MDR-TB in Finland – still rare despite the
situation in our neighbouring countries. Clin Respir J. 2012:35–9.
48. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-
resistant tuberculosis in France: a nationwide case–control study. Am J
Respir Crit Care Med. 1999;160:587–93.
49. Blaas SH, Mutterlein R, Weig J, Neher A, Salzberger B, Lehn N. Extensively
drug resistant tuberculosis in a high income country: a report of four
unrelated cases. BMC Infect. Dis. 2008. http://ovidsp.ovid.com/ovidweb.
cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=351803792.
50. Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri MV, et al.
Outcome of treatment of MDR-TB patients with standardised regimens, Iran,
2002–2006. Int J Tuberc Lung Dis. 2008;12:750–5.
51. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, Casali L, Fiorentini
F, Codecasa LR, Migliori GB. Management of multidrug-resistant tuberculosis in
Italy. Int J Tuberc Lung Dis. 2005:507–13. http://ovidsp.ovid.com/ovidweb.
cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=40646836.
52. Manfredi R, Nanetti A, Dal Monte P, Calza L. Increasing pathomorphism of
pulmonary tuberculosis. An observational study of slow clinical,
Nellums et al. BMC Medicine  (2018) 16:27 Page 10 of 11
microbiological and imaging response of lung tuberculosis to specific
treatment. Which role for linezolid? Brazilian J Infect Dis. 2009;13:297–303.
http://www.scielo.br/pdf/bjid/v13n4/v13n4a12.pdf.
53. Mignone F, Codecasa LR, Scolfaro C, Raffaldi I, Lancella L, Ferrarese M,
Garazzino S, Marabotto C, Esposito S, Gabiano C, Lipreri R. The spread of
drug-resistant tuberculosis in children: an Italian case series. Epidemiol
Infect. 2014:2049–56. http://journals.cambridge.org/action/
displayJournal?jid=HYG.
54. Cameron RJ, Harrison AC. Multidrug resistant tuberculosis in Auckland
1988–95. NZ Med J. 1997:119–22. http://ovidsp.ovid.com/ovidweb.cgi?T=
JS&PAGE=reference&D=emed7&NEWS=N&AN=27151718.
55. Kherad O, Herrmann FR, Zellweger JP, Rochat T. Clinical presentation,
demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year
study in Geneva, Switzerland. BMC Infect Dis. 2009. http://ovidsp.ovid.com/
ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=358128735.
56. Ferrer G, Acuna-Villaorduna C, Escobedo M, Vlasich E. Outcomes of
multidrug-resistant tuberculosis among binational cases in El Paso, Texas.
Am J Trop Med Hyg. 2010:1056–8. http://www.ajtmh.org/content/83/5/
1056.full.pdf+html.
57. Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for
multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and
meta-analysis of published studies. Infect Dis Poverty. 2017;6:7. http://
idpjournal.biomedcentral.com/articles/https://doi.org/10.1186/s40249-016-
0214-x, Accessed 22 July 2017.
58. Karo B, Hauer B, Hollo V, van der Werf M, Fiebig L, Haas W. Tuberculosis
treatment outcome in the European Union and European Economic Area:
an analysis of surveillance data from 2002–2011. Eurosurveillance. 2015;20:1–
10. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=
fulltext&D=emed17&AN=607282154.
59. Tang Y, Zhao M, Wang Y, Gong Y, Yin X, Zhao A, et al. Non-adherence to
anti-tuberculosis treatment among internal migrants with pulmonary
tuberculosis in Shenzhen, China: a cross-sectional study. BMC Public Health.
2015;15:474. http://www.ncbi.nlm.nih.gov/pubmed/25952360, Accessed 28
July 2017.
60. Zhou C, Chu J, Liu J, Gai Tobe R, Gen H, Wang X, et al. Adherence to
tuberculosis treatment among migrant pulmonary tuberculosis patients in
Shandong, China: a quantitative survey study. PLoS One. 2012;7:e52334.
http://dx.plos.org/10.1371/journal.pone.0052334, Accessed 28 July 2017.
61. Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. Risk
factors and mortality associated with default from multidrug-resistant
tuberculosis treatment. Clin Infect Dis. 2008;46:1844–51. http://www.ncbi.
nlm.nih.gov/pubmed/18462099, Accessed 28 July 2017.
62. Abarca Tomas B, Pell C, Bueno Cavanillas A, Guillen Solvas J, Pool R, Roura
M. Tuberculosis in migrant populations. a systematic review of the
qualitative literature. PLoS One. 2013;2440(8):e8. http://ovidsp.ovid.com/
ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=cagh&AN=
20143072209.
63. Priebe S, Sandhu S, Dias S, Gaddini A, Greacen T, Ioannidis E, et al. Good practice
in health care for migrants: views and experiences of care professionals in 16
European countries. BMC Public Health BioMed Central. 2011;11:187.
64. Woodward A, Howard N, Wolffers I. Health and access to care for
undocumented migrants living in the European Union: a scoping review.
Health Policy Plan. 2014;29:818–30.
65. Lin S, Melendez-Torres GJ. Systematic review of risk factors for
nonadherence to TB treatment in immigrant populations. Trans R Soc Trop
Med Hyg. 2016;110:268–80.
66. Minetti A, Camelique O, Hsa Thaw K, Thi S, Swaddiwudhipong W, Hewison C,
et al. Tuberculosis treatment in a refugee and migrant population: 20 years of
experience on the Thai–Burmese border. Int J Tuberc Lung Dis. 2010;14:1589–
95. http://www.ncbi.nlm.nih.gov/pubmed/21144245, Accessed 21 July 2017.
67. Department of Health UHO. Memorandum of understanding between
health and social care information centre and the Home Office and the
Department of Health. 2017. https://www.gov.uk/government/uploads/
system/uploads/attachment_data/file/585928/MOU_v3.pdf.
68. van der Oest C, Chenhall R, Hood D, Kelly P. Talking about TB: multicultural
diversity and tuberculosis services in Waikato, New Zealand. NZ Med J. 2005;118:
U1496. http://www.ncbi.nlm.nih.gov/pubmed/15937530, Accessed 29 July 2017.
69. OECD. Health expenditure in relation to GDP. Health at a Glance 2015:
OECD Indicators. 2015. http://www.oecd-ilibrary.org/docserver/download/
8115071ec060.pdf?expires=1501169037&id=id&accname=guest&checksum=
BFD96C2D1A8F14397C00D75BAED8ED1C.
70. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with
DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths:
decision analysis. BMJ. 2003;326:574. http://www.ncbi.nlm.nih.gov/pubmed/
12637401, Accessed 28 July 2017.
71. Grover GS, Takkar J. Recent advances in multi-drug-resistant tuberculosis
and RNTCP. Indian J Community Med. 2008;33:219–23. http://www.ncbi.nlm.
nih.gov/pubmed/19876493, Accessed 28 July 2017.
72. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient
adherence to tuberculosis treatment: a systematic review of qualitative
research. PLoS Med. 2007;4:e238. http://www.ncbi.nlm.nih.gov/pubmed/
17676945, Accessed 29 July 2017.
73. Public Health England. Collaborative tuberculosis strategy for England 2015
to 2020. Public Health England. 2015.
74. WHO Regional Office for Europe. Roadmap to implement the tuberculosis
action plan for the WHO European region 2016–2020: towards ending
tuberculosis and multidrug-resistant tuberculosis. 2016. http://www.euro.
who.int/__data/assets/pdf_file/0020/318233/50148-WHO-TB-Plan_May17_
web.pdf?ua=1.
75. Dara M, de Colombani P, Petrova-Benedict R, Centis R, Zellweger JP,
Sandgren A, et al. Minimum package for cross-border TB control and care in
the WHO European region: a Wolfheze consensus statement. Eur Respir J.
2012;40:1081–90.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Nellums et al. BMC Medicine  (2018) 16:27 Page 11 of 11
